Technology
Revolutionizing ADCs with precision and innovation
Breakthrough
Linker Technology
Baylink's novel linkers expand payload diversity, enabling use of hydrophobic drugs.
Unique design features are incorporated in the linker technology to reduce off-target effects and improve payload delivery to tumors.
Innovative
Payloads
Baylink is developing innovative payloads beyond TOP1i and MMAE payloads.
Protein degrader ADCs using molecular glues and PROTAC payloads offer new therapeutic approaches and are under development
at Baylink.
Addressing
Key Challenges
Baylink tackles critical issues: improving therapeutic index, expanding payload diversity, and overcoming resistance.
This drives the next wave
of precision ADCs.
News
Get the latest updates from us
Baylink Biosciences Announces FDA Clearance of IND Application for BLB101, a Novel CLDN6/CLDN9 Dual-Targeting ADC for Advanced Solid Tumors
[August 13, 2026] — Baylink Biosciences, Inc. (“Baylink”), a biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) for the treatment of solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for BLB101, a novel CLDN6/CLDN9 dual-targeting ADC for the treatment of patients with advanced solid tumors. BLB101 is Baylink’s lead ADC program and is designed to selectively deliver...
Aug 14, 2026
97
Baylink Biosciences to Present Its Novel Linker and Payload Technologies at 3rd ADC Linker & Conjugation Summit
PALO ALTO, CA, UNITED STATES, August 13, 2025 -- Baylink Biosciences, a biotechnology ...
Dec 5, 2025
494
Baylink Presents New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting
PALO ALTO, Calif., April 25, 2025 -- Baylink Biosciences presented data from its Antibody Drug Conjugate portfolio ...
Apr 25, 2025
883